Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and commercializes diagnostic tests primarily based on polymerase chain reaction (PCR) technology. The company operates within the biotechnology and in vitro diagnostics industries, with a focus on infectious disease detection for human and veterinary applications. Its core competency lies in proprietary assay design and reagent formulation intended to improve test sensitivity, specificity, and cost efficiency.
The company’s primary revenue drivers have historically included diagnostic test kits for infectious diseases, most notably COVID-19 during the pandemic period, as well as tests for other respiratory, tropical, and agricultural pathogens. Co-Diagnostics serves clinical laboratories, public health organizations, government agencies, and research institutions globally. Founded in 2013 and headquartered in Utah, the company gained public market exposure through its listing on Nasdaq and expanded rapidly during the COVID-19 pandemic, after which it shifted strategic focus toward platform-based diagnostics and broader infectious disease applications as pandemic-related demand declined.
Business Operations
Co-Diagnostics operates primarily through the development and commercialization of molecular diagnostic tests using its proprietary Logix Smart™ technology, which is designed to identify unique genomic regions of pathogens to enhance test performance. Revenue is generated from the sale of diagnostic test kits, reagents, and related consumables, with sales historically concentrated in PCR-based assays. The company also develops multiplex tests and has pursued diagnostic platforms intended to decentralize and simplify molecular testing.
Operations include both domestic manufacturing and international distribution, supported by internal research and development capabilities. The company controls its assay design software, intellectual property related to primer and probe design, and certain manufacturing processes. Its wholly owned subsidiary, Co-Diagnostics Ireland Limited, supports international operations, regulatory activities, and distribution outside the United States. Data inconclusive based on available public sources regarding material joint ventures beyond disclosed subsidiaries.
Strategic Position & Investments
Strategically, Co-Diagnostics has sought to transition from reliance on single-disease testing toward a diversified menu of infectious disease diagnostics and integrated testing platforms. Growth initiatives have included investment in point-of-care and near-patient testing solutions, as well as expanding test menus for respiratory, gastrointestinal, and vector-borne diseases. The company has emphasized scalability and adaptability of its technology to respond to emerging pathogens.
Notable investments have included continued funding of internal R&D and the advancement of its proprietary diagnostic platform initiatives. Co-Diagnostics has historically avoided large-scale acquisitions, instead prioritizing organic development and selective technology investments. Emerging areas of focus include multiplex diagnostics, portable PCR systems, and applications in global health and agricultural testing, though the commercial impact of these initiatives remains evolving based on publicly available disclosures.
Geographic Footprint
Co-Diagnostics is headquartered in North America, with its principal executive offices in the United States. The company maintains a global market presence through direct sales, distributors, and subsidiary operations, particularly in Europe, Asia, Latin America, and Africa, where its diagnostic tests have been supplied to government and public health customers.
International operations are supported by regulatory approvals and distribution relationships across multiple continents, enabling participation in both developed and emerging markets. While the United States has historically represented a significant portion of revenue, especially during the COVID-19 pandemic, international markets have been a critical component of the company’s commercial strategy and revenue diversification.
Leadership & Governance
Co-Diagnostics is led by an executive team with experience in molecular diagnostics, biotechnology commercialization, and global health markets. The company’s leadership emphasizes scientific rigor, rapid assay development, and disciplined capital allocation in navigating post-pandemic market conditions.
Key executives include:
- Dwight Egan – Chief Executive Officer
- Brian Brown – Chief Financial Officer
- Aaron Vine – Chief Operating Officer
- Paul Koepf – Chief Scientific Officer
- Kimberly Yates – General Counsel and Corporate Secretary
The board of directors provides governance oversight with a focus on regulatory compliance, risk management, and long-term shareholder value, consistent with disclosures in SEC filings.